enGene Therapeutics Inc. 8-K

What Happened

• enGene Therapeutics Inc. filed a Form 8-K on July 16, 2026 announcing that Dr. Richard Glickman resigned as a director and chairman of the Board effective July 15, 2026. The company said the resignation was not due to any disagreement with the company on operations, policies or practices. Current board member Michael Heffernan was appointed chairman, and the company issued a press release dated July 16, 2026 to announce the change.

Key Details

• Dr. Richard Glickman notified the company of his resignation on July 15, 2026; the resignation was effective immediately.
• The company expressly stated the resignation was not due to any disagreement with the company’s operations, policies or practices.
• Michael Heffernan, an existing board member, was appointed chairman and the appointment was announced in a press release (Exhibit 99.1) filed with the 8-K on July 16, 2026.
• The Form 8-K was signed by Ronald H. W. Cooper, Chief Executive Officer and President, on July 16, 2026.

Why It Matters

• This is a board-level leadership change (chairman), not a reported change in executive management (CEO/CFO). For investors, that typically signals a governance update rather than an immediate operational shift.
• The filing’s note that the resignation was not due to disagreement reduces the likelihood that the change reflects internal conflict; investors may still want to monitor future disclosures for any strategic or governance implications.
• Watch for additional communications from enGene (press releases, proxy materials, or SEC filings) that might outline any board committee reassignments or governance changes following the new chair appointment.